Sunday, December 21, 2014 Last update: Yesterday, 8:33 AM
FreshNews.com - Covering Large & Obscure Tech Companies Since 1996

Matinas BioPharma Announces Presentation at Biotech Showcase 2014 in San Francisco on Tuesday, January 14, 2013

Companies mentioned in this article: Matinas BioPharma Holdings, Inc.

BEDMINSTER, NJ--(Marketwired - January 10, 2014) - Matinas BioPharma Holdings, Inc., an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular conditions, announced today that it will be presenting at Biotech Showcase 2014. The 6th annual investor and partnering conference is being held January 13-15, 2014 at the Parc 55 Wyndham - Union Square, San Francisco, CA.

Roelof Rongen, Chief Executive Officer, will provide an overview of Matinas BioPharma's business during the live presentation on Tuesday, January 14, 2014 at 11:45 a.m. PT (2:45 p.m. ET). Mr. Rongen's presentation will include the Company's business outlook for 2014, an overview of the development of its lead product candidate, MAT9001, and key milestones expected over the next 12 months.

About MAT9001
Matinas BioPharma is developing MAT9001 for therapeutic applications, with severe hypertriglyceridemia (TG>500 mg/dL) and mixed dyslipidemia (TG 200-499 mg/d with concomitant statin therapy) as the lead indications. Based on promising early data, the Company is preparing to file an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration and conduct a human study in the first half of 2014. Assuming positive data from this study, Matinas BioPharma anticipates commencing the first of its pivotal Phase 3 registration studies in 2014. The Company believes that the composition of MAT9001 represents a significantly differentiated lipid profile, providing unique clinical benefits.

About Matinas BioPharma
Matinas BioPharma Holdings, Inc. is an early stage privately-held biopharmaceutical company focused on the development of omega-3-based prescription therapeutics for the treatment of cardiovascular conditions. The Company's lead product candidate, MAT9001, is designed for treatment of severe hypertriglyceridemia (TG>500 mg/dl) and mixed dyslipidemia (TG 200-499 mg/dl while on statin therapy). The Matinas BioPharma management team brings a cumulative multi-decade omega-3 pharmaceutical experience to the Company, providing a unique perspective and capability for the development of the next generation of omega-3-fatty acid-based pharmaceutical products.

For more information, please visit www.matinasbiopharma.com.

Forward Looking Statements: This release contains "forward-looking statements", including those related to the Company's strategic focus and the future development MAT9001. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of MAT9001; our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials for MAT9001; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.


Contact:

Investor and Media Contact
Jenene Thomas
Investor Relations and Corporate Communications Advisor
Jenene Thomas Communications, LLC
Phone: +1 (908) 938-1475 
Email: Jthomas@matinasbiopharma.com